The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Keunchil Park
Consultant or Advisory Role - Roche (U)
Chun-Ming Tsai
No relevant relationships to disclose
Myung-ju Ahn
No relevant relationships to disclose
Chong-Jen Yu
Consultant or Advisory Role - AstraZeneca; Pfizer
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Roche; Sanofi
Sang-We Kim
No relevant relationships to disclose
Virote Sriuranpong
Research Funding - Roche
Han Pin Kuo
Research Funding - Roche
Jong-Seok Lee
No relevant relationships to disclose
Jin Hyoung Kang
No relevant relationships to disclose
Meng-Chih Lin
Research Funding - Roche
Sarayut Lucien Geater
No relevant relationships to disclose
Gee-Chen Chang
No relevant relationships to disclose
Kasan Seetalarom
No relevant relationships to disclose
Ping Fai Peter So
No relevant relationships to disclose
Ruay-Sheng Lai
No relevant relationships to disclose
Ashley Chi Kin Cheng
No relevant relationships to disclose
Eun Kyung Cho
No relevant relationships to disclose
Shang-Hung Chen
No relevant relationships to disclose
Te-Chun Hsia
No relevant relationships to disclose
Tony Mok
Employment or Leadership Position - The Chinese University of HongKong
Consultant or Advisory Role - AstraZeneca; AVEO; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Lilly; Merck Serono; Pfizer; Roche; Taiho Pharmaceutical
Honoraria - AstraZeneca; AVEO; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Lilly; Merck Serono; Pfizer; Roche; Taiho Pharmaceutical
Research Funding - AstraZeneca